ライフサイエンスコーパス: esophagitis

1 d acid-related disease (peptic ulcer, reflux esophagitis).

2 racterize the underlying molecular events in esophagitis.

3 re may be indicative of underlying lichenoid esophagitis.

4 ageal stricture (grade 2) and 1 (2%) grade 4 esophagitis.

5 gs were considered compatible with lichenoid esophagitis.

6 P = .001), and all patients had evidence of esophagitis.

7 sy specimens from patients with eosinophilic esophagitis.

8 ronic rhinosinusitis (CRS), and eosinophilic esophagitis.

9 prescribed for the treatment of eosinophilic esophagitis.

10 18 with achalasia, and 15 with eosinophilic esophagitis.

11 and IgG4 in the development of eosinophilic esophagitis.

12 associated with postoperative dysphagia and esophagitis.

13 butions in our understanding of eosinophilic esophagitis.

14 ophageal candidiasis, and 2 had eosinophilic esophagitis.

15 umnar epithelial metaplasia caused by reflux esophagitis.

16 a low prevalence of new-onset dysphagia and esophagitis.

17 of gastroesophageal reflux disease, such as esophagitis.

18 distinguished from noneosinophilic forms of esophagitis.

19 al-like columnar metaplasia linked to reflux esophagitis.

20 and patients with chronic (noneosinophilic) esophagitis.

21 n children and adolescents with eosinophilic esophagitis.

22 n children and adolescents with eosinophilic esophagitis.

23 bowel disease, small-bowel obstruction, and esophagitis.

24 role for periostin in allergic eosinophilic esophagitis.

25 ountered and well studied EGID, eosinophilic esophagitis.

26 t licensed for the treatment of eosinophilic esophagitis.

27 he esophagus recovers from radiation-induced esophagitis.

28 ophilic disorders, most notably eosinophilic esophagitis.

29 d in atopic disorders including eosinophilic esophagitis.

30 1.2%, respectively; P < .001), and mucositis/esophagitis (18.6% v 14.4%, respectively; P = .0246).

31 nce: 0.19; 95% CI: -0.07 to 0.46; P = 0.15), esophagitis (19% vs 13%; RR: 1.42; 95% CI: 0.69-2.91; P

32 3 to 4 pneumonitis (12% vs 9%; P = .12) and esophagitis (23% vs 21%; P = .27) were similar.

33 e Pneumocystis pneumonia (PCP, 28%), Candida esophagitis (23%), and Kaposi sarcoma (KS, 16%).

34 inority of patients had heartburn (24.3%) or esophagitis (27.4%), and these patients were successfull

35 The principal toxicity was esophagitis (29% grade 3 or 4 esophagitis, with one pati

36 We evaluated MI in 61 patients with erosive esophagitis, 81 with nonerosive but pH-abnormal GERD, 93

37 inflammatory tissue focused on eosinophilic esophagitis, a prototypic, chronic, allergic disease, wh

38 adequate PPI response, and absence of severe esophagitis, acid exposure on reflux monitoring predicte

39 Severe erosive esophagitis after a 2-month course of proton-pump inhibi

40 ory diseases, including asthma, eosinophilic esophagitis, allergic rhinitis, and atopic dermatitis.

41 control, 82% ceased PPI therapy, 100% healed esophagitis and 45% normalized EAE.

42 h normal pH metry, 2 were found with erosive esophagitis and 7 without endoscopic abnormalities.

43 ology, including 22% with moderate to severe esophagitis and 7% with Barrett's esophagus.

44 specimens from 11 subjects with eosinophilic esophagitis and 8 without (controls) were assessed for I

45 specimens from 24 subjects with eosinophilic esophagitis and 9 without (controls).

46 ld be considered high risk to develop reflux esophagitis and advised of the management considerations

47 MI was measured at the site of esophagitis and at 2, 5, and 10 cm above the squamocolum

48 Subsequent esophagitis and BE can be a serious unintended sequalae.

49 e esophageal epithelium (EE), such as reflux esophagitis and cancer, are rising in incidence.

50 of immune cell-mediated esophageal injury in esophagitis and confirms the utility of the OTC platform

51 , SSc patients may be complicated by erosive esophagitis and eventually by Barrett's esophagus and es

52 collected from 15 subjects with eosinophilic esophagitis and from 41 without (controls), and assayed

53 is a significant risk factor, such as reflux esophagitis and gallstones.

54 IKKbetaca mice developed esophagitis and had increased numbers of blood vessels i

55 No such difference was observed between mid-esophagitis and healthy controls.

56 data indicating considerably lower risks of esophagitis and heartburn (63% relative reduction), dump

57 psies are obtained in the setting of erosive esophagitis and if pathology findings suggest LGD, or if

58 egan, the groups with histologic evidence of esophagitis and normal histologies did not differ in sev

59 as an association of H. pylori genotype with esophagitis and PUD.

60 opose a link between both healing of erosive esophagitis and the slower remission of upper and lower

61 32 (G allele protective against eosinophilic esophagitis) and rs2416257 (A allele associated with low

62 % grade 4 hematologic toxicities, 8% grade 3 esophagitis, and 7% grade 3 to 4 pneumonitis.

63 lation in asthma, food allergy, eosinophilic esophagitis, and allergic rhinosinusitis.

64 e of gastroesophageal reflux disease (GERD), esophagitis, and Barrett's esophagus (BE) after sleeve g

65 The primary outcome was prevalence of GERD, esophagitis, and BE after SG.

66 The postoperative prevalence of GERD, esophagitis, and BE following SG is significant.

67 , GBP reduces GERD symptoms, improves reflux esophagitis, and decreases esophageal acid exposure for

68 any diseases, including asthma, eosinophilic esophagitis, and eczema.

69 intestinal symptoms overlapping with erosive esophagitis, and provides sustained improvement in HRQoL

70 after LNF, and esophageal acid exposure and esophagitis are similar, with no differences in heartbur

71 20% of patients in the LHM group had reflux esophagitis, as assessed by endoscopy; at 24 months, the

72 ty: gastroesophageal reflux disease, erosive esophagitis, Barrett's esophagus, esophageal adenocarcin

73 proven GERD (ie, positive pH study, erosive esophagitis, Barrett's esophagus, or esophageal ulcer),

74 henocopies human pathology with evolution of esophagitis, Barrett-like metaplasia and EAC.

75 od allergy in the pig can be associated with esophagitis based on histological and endoscopic finding

76 complexes were found in 2 of 5 eosinophilic esophagitis biopsy specimens based on ultrastructural an

77 ens from 21 of 24 patients with eosinophilic esophagitis, but in none of the specimens from 9 control

78 Eosinophilic esophagitis can now be treated with biologic agents that

79 Lichenoid esophagitis causing death has not been reported previous

80 only slightly in patients with eosinophilic esophagitis, compared with controls.

81 er in the group with histologic evidence for esophagitis, compared with patients who had normal histo

82 my samples from 2 patients with eosinophilic esophagitis contained 180 and 300 IgG4 plasma cells/maxi

83 0 controls, stored in the Swiss Eosinophilic Esophagitis Database (SEED) and Biobank, were analyzed.

84 hallenged the traditional notion that reflux esophagitis develops when esophageal surface epithelial

85 ed the majority of the clinical Eosinophilic Esophagitis Diagnostic Profile (EDP) on fluidic transcri

86 and sex-matched subjects with mid-esophagus esophagitis (diseased-control), and histologically norma

87 tumor location, institution accrual volume, esophagitis/dysphagia, planning target volume and heart

88 Eosinophilic esophagitis (EoE) afflicts both children and adults.

89 dose reduction in patients with eosinophilic esophagitis (EoE) and analyzed esophageal transcriptomes

90 Th2 and inflammatory milieu of eosinophilic esophagitis (EoE) and assessed alterations in smooth mus

91 An association between eosinophilic esophagitis (EoE) and celiac disease (CD) has been sugge

92 Patients with eosinophilic esophagitis (EoE) and extremely high esophageal eosinoph

93 cur frequently in patients with eosinophilic esophagitis (EoE) and harbor a risk for severe esophagea

94 epresenting 2 entities known as eosinophilic esophagitis (EoE) and PPI-responsive esophageal eosinoph

95 eeded to assess the activity of eosinophilic esophagitis (EoE) and to provide end points for clinical

96 ue from individuals with active eosinophilic esophagitis (EoE) and were present at markedly higher le

97 Fibrostenosis, the most serious eosinophilic esophagitis (EoE) complication, is mediated by epithelia

98 Eosinophilic esophagitis (EoE) exhibits esophageal dysfunction owing

99 n (IL)-5 in the pathogenesis of eosinophilic esophagitis (EoE) has been established in animal models;

100 A high prevalence of eosinophilic esophagitis (EoE) has been preliminarily reported in pat

101 Eosinophilic esophagitis (EoE) has emerged over the past 2 decades as

102 d translation, in patients with eosinophilic esophagitis (EoE) has not been explored.

103 Thus far, eosinophilic esophagitis (EoE) has received the most focus, leading t

104 inks between food allergens and eosinophilic esophagitis (EoE) have been established, but the interpl

105 elial fibrosis in subjects with eosinophilic esophagitis (EoE) have not been delineated.

106 Topical steroid treatments for eosinophilic esophagitis (EoE) include swallowed fluticasone from a m

107 Eosinophilic esophagitis (EoE) is a chronic allergic disease associat

108 Eosinophilic esophagitis (EoE) is a chronic allergic disease with lim

109 Eosinophilic esophagitis (EoE) is a chronic and increasingly prevalen

110 Eosinophilic esophagitis (EoE) is a chronic antigen-driven allergic i

111 Eosinophilic esophagitis (EoE) is a chronic antigen-mediated clinicop

112 Eosinophilic esophagitis (EoE) is a chronic antigen-mediated disease

113 Eosinophilic esophagitis (EoE) is a chronic disease characterized cli

114 Eosinophilic esophagitis (EoE) is a chronic immune/antigen-mediated c

115 Eosinophilic esophagitis (EoE) is a chronic inflammatory condition of

116 Eosinophilic esophagitis (EoE) is a chronic inflammatory disease that

117 Eosinophilic esophagitis (EoE) is a chronic inflammatory disease with

118 Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder ass

119 Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder.

120 Eosinophilic esophagitis (EoE) is a chronic TH2 inflammatory disease

121 Eosinophilic esophagitis (EoE) is a chronic, esophageal, type 2 infla

122 Eosinophilic esophagitis (EoE) is a chronic, food antigen-mediated di

123 Eosinophilic esophagitis (EoE) is a chronic, immune/antigen-mediated

124 Eosinophilic esophagitis (EoE) is a chronic, inflammatory disease of

125 Eosinophilic esophagitis (EoE) is a chronic, Th2-type inflammatory di

126 Eosinophilic esophagitis (EoE) is a clinicopathologic entity of incre

127 Eosinophilic esophagitis (EoE) is a condition characterized by dense

128 Eosinophilic esophagitis (EoE) is a food allergy-associated inflammat

129 Eosinophilic esophagitis (EoE) is a new disease.

130 Like many rare diseases, eosinophilic esophagitis (EoE) is a poorly understood disorder, and a

131 Eosinophilic esophagitis (EoE) is a rapidly emerging, chronic inflamm

132 Eosinophilic esophagitis (EoE) is a recently described disease in whi

133 Eosinophilic esophagitis (EoE) is a recently recognized inflammatory

134 Eosinophilic esophagitis (EoE) is a relatively new disease that has r

135 Eosinophilic esophagitis (EoE) is a severe inflammatory disease of th

136 Eosinophilic esophagitis (EoE) is a Th2 cytokine-associated disease c

137 Eosinophilic esophagitis (EoE) is an allergen-mediated inflammatory d

138 Eosinophilic esophagitis (EoE) is an allergic disease of increasing w

139 Eosinophilic esophagitis (EoE) is an allergic disorder characterized

140 Eosinophilic esophagitis (EoE) is an antigen-mediated eosinophilic di

141 Eosinophilic esophagitis (EoE) is an atopic disease characterized by

142 Eosinophilic esophagitis (EoE) is an emerging chronic inflammatory di

143 Eosinophilic esophagitis (EoE) is an emerging tissue-specific allergi

144 Eosinophilic esophagitis (EoE) is an emerging, chronic, rare allergic

145 Eosinophilic esophagitis (EoE) is an eosinophil-rich, T(H)2 antigen-m

146 Eosinophilic esophagitis (EoE) is an esophageal disorder predominantl

147 Eosinophilic esophagitis (EoE) is an esophageal inflammatory disease

148 Eosinophilic esophagitis (EoE) is an inflammatory disorder of the eso

149 Although eosinophilic esophagitis (EoE) is associated with certain gene varian

150 The pathology of eosinophilic esophagitis (EoE) is characterized by eosinophil-rich in

151 Treatment failure in eosinophilic esophagitis (EoE) is common.

152 The incidence of eosinophilic esophagitis (EoE) is greater in male than female subject

153 The prevalence of Eosinophilic esophagitis (EoE) is increasing, a severe complication o

154 Pharmacologic treatment of eosinophilic esophagitis (EoE) is limited to off-label use of cortico

155 IMS: Pharmacologic treatment of eosinophilic esophagitis (EoE) is limited to off-label use of cortico

156 Eosinophilic esophagitis (EoE) is often associated with atopic airway

157 logic and molecular features of eosinophilic esophagitis (EoE) is unclear.

158 e observed an increased risk of eosinophilic esophagitis (EoE) mostly among first-degree relatives, s

159 Eosinophilic esophagitis (EoE) now represents a commonly recognized d

160 Patients with eosinophilic esophagitis (EoE) often become dysphagic from the combin

161 h the increasing recognition of eosinophilic esophagitis (EoE) over the past two decades, pharmacolog

162 Diagnostic evaluation of eosinophilic esophagitis (EoE) remains difficult, particularly the as

163 agnosis and/or recrudescence of eosinophilic esophagitis (EoE) remains unclear, with some studies dem

164 y to trigger allergies achieves eosinophilic esophagitis (EoE) remission in children, data on its pro

165 BACKGROUND & AIMS: Adults with eosinophilic esophagitis (EoE) typically present with dysphagia and f

166 Eosinophilic esophagitis (EoE) was historically distinguished from ga

167 Eosinophilic esophagitis (EoE) was recognized as its own entity in th

168 ological findings suggestive of eosinophilic esophagitis (EoE) who achieve complete remission on PPI

169 ic tissue inflammation, such as eosinophilic esophagitis (EoE), a chronic inflammatory disorder trigg

170 Eosinophilic esophagitis (EoE), a food antigen-mediated disease, is e

171 nized as a primary treatment of eosinophilic esophagitis (EoE), an allergic inflammatory disease of t

172 ecular and cellular etiology of eosinophilic esophagitis (EoE), an emerging tissue-specific allergic

173 23) of patients with achalasia, eosinophilic esophagitis (EoE), and gastroesophageal reflux disease (

174 the pathologic understanding of eosinophilic esophagitis (EoE), as of yet, no single agent has been a

175 id increase in the incidence of eosinophilic esophagitis (EoE), but potential exposures have not been

176 In patients with eosinophilic esophagitis (EoE), eosinophils accumulate and release gr

177 hological conditions, including eosinophilic esophagitis (EoE), in which basal progenitor cells becom

178 tissue pathology during active eosinophilic esophagitis (EoE), providing additional evidence for blo

179 pic, and histologic features of eosinophilic esophagitis (EoE), review the current diagnostic guideli

180 n emerging form of esophagitis, eosinophilic esophagitis (EoE), which is currently diagnosed by histo

181 een used to treat patients with eosinophilic esophagitis (EoE), yielding varied results.

182 ia is the main symptom of adult eosinophilic esophagitis (EoE).

183 timate the biologic activity of eosinophilic esophagitis (EoE).

184 pic procedures in patients with eosinophilic esophagitis (EoE).

185 geal reflux disease (GERD), and eosinophilic esophagitis (EoE).

186 major concern for patients with eosinophilic esophagitis (EoE).

187 pria is a known complication of eosinophilic esophagitis (EoE).

188 l corticosteroid treatments for eosinophilic esophagitis (EoE).

189 QOL) of pediatric patients with Eosinophilic Esophagitis (EoE).

190 comorbidities in patients with eosinophilic esophagitis (EoE).

191 ageal reflux disease (GERD) and eosinophilic esophagitis (EoE).

192 ssue-specific allergic disease, eosinophilic esophagitis (EoE).

193 ny allergic diseases, including eosinophilic esophagitis (EoE).

194 ended as first-line therapy for eosinophilic esophagitis (EoE).

195 mination diets in patients with eosinophilic esophagitis (EoE).

196 from the diets of patients with eosinophilic esophagitis (EoE).

197 ytokines in the pathogenesis of eosinophilic esophagitis (EoE); however, heterogeneity in type 2 gene

198 pproach for diagnosis of an emerging form of esophagitis, eosinophilic esophagitis (EoE), which is cu

199 tercellular space width, endoscopic grade of esophagitis, esophageal acid exposure, and mucosal imped

200 and is associated with an increased risk of esophagitis, esophageal strictures, Barrett esophagus, a

201 Eosinophilic esophagitis experts were surveyed to estimate the preval

202 initis, chronic rhinosinusitis, eosinophilic esophagitis, food allergy, and atopic dermatitis.

203 n symptoms of GERD and those of eosinophilic esophagitis, functional dyspepsia, and gastroparesis, po

204 Esophagitis further healed in 75% (6/8) of patients.

205 icemia, nutritional and metabolic disorders, esophagitis, gastroenteritis, and digestive disorders we

206 controlled trial of adults with eosinophilic esophagitis given an antibody against IgE (omalizumab, n

207 was defined by abnormal pH-testing or reflux esophagitis >Los Angeles grade A.

208 geal tissues from patients with eosinophilic esophagitis had a 45-fold increase in IgG4 compared with

209 Subjects with eosinophilic esophagitis had increased serum levels of IgG4 that reac

210 fter nCRT, suggesting that radiation-induced esophagitis had mostly resolved by that time.

211 Eosinophilic esophagitis has been reported as a complication of oral

212 Treatment of eosinophilic esophagitis has progressed from elemental formula for ch

213 nCRT and to determine when radiation-induced esophagitis has resolved.

214 Patients with eosinophilic esophagitis have increased numbers of mucosal mast cells

215 provide further elimination of symptoms and esophagitis healing.

216 mary outcomes were esophageal acid exposure, esophagitis, heartburn score, dilatation for dysphagia,

217 hed patients with EoE from those with reflux esophagitis, identified by pH-impedance testing.

218 to as the EDP) that identifies patients with esophagitis in a fast, objective, and mechanistic manner

219 e animal model for the study of eosinophilic esophagitis in humans.

220 ons of anti-TNF prevented the development of esophagitis in IKKbetaca mice.

221 te cupping of reflux symptoms and healing of esophagitis in patients with GERD.

222 e a case, diagnosed by autopsy, of lichenoid esophagitis in which massive bleeding from generalized e

223 ents (drug inefficacy, gastritis, and reflux esophagitis) in two patients were considered related to

224 d HEWP, endoscopy revealed clinical signs of esophagitis including oedema, granularity, white spots,

225 Eosinophilic esophagitis is a chronic allergic disease with insuffici

226 Eosinophilic esophagitis is a chronic, immune-mediated inflammatory d

227 Eosinophilic esophagitis is a clinicopathologic disease of increasing

228 Lichenoid esophagitis is an appropriate diagnostic term when clini

229 Eosinophilic esophagitis is an emerging disease that is distinguished

230 By contrast, eosinophilic esophagitis is characterized by low levels of IgE specif

231 le of specific foods in causing eosinophilic esophagitis is elucidated by several studies, and microR

232 oods, indicate that, in adults, eosinophilic esophagitis is IgG4-associated, and not an IgE-induced a

233 Eosinophilic esophagitis is usually triggered by foods, by unclear me

234 "Lichenoid esophagitis" is a descriptive term for a lichenoid patte

235 Eosinophilic esophagitis-like esophageal inflammation was induced in

236 the presence of active inflammation (erosive esophagitis, Los Angeles grade C and D).

237 rt the role of the allergist in eosinophilic esophagitis management, especially for food allergen tes

238 ortant for successful long-term eosinophilic esophagitis management.

239 Eosinophilic esophagitis may affect individuals at any age, although

240 ings suggest that the pathogenesis of reflux esophagitis may be cytokine-mediated rather than the res

241 lustrated here for the first time, lichenoid esophagitis may cause ulceration and mucosal sloughing s

242 The association of minimal change esophagitis (MCE) with GERD is controversial.

243 t development phase, the PedsQL Eosinophilic Esophagitis Module is now undergoing multisite national

244 tent validity of the new PedsQL Eosinophilic Esophagitis Module items was supported in the current in

245 lity of Life Inventory (PedsQL) Eosinophilic Esophagitis Module.

246 to groups with histologic evidence of reflux esophagitis (n = 50), or normal histology results (n = 5

247 rformed a prospective study of patients with esophagitis (n = 8) or Barrett's esophagus (n = 6); medi

248 astric/duodenal ulcer (n=2), and hemorrhagic esophagitis (n=1).

249 Secondary outcomes included healing of esophagitis, normalization of EAE and PPI use after TF.

250 Treatment-related grade >=3 dysphagia and esophagitis occurred in 3.2% and 5.0% of patients in the

251 22 with EoE, and 20 with GERD (symptoms plus esophagitis or + reflux study) were analyzed.

252 ents were classified as having GERD (erosive esophagitis or abnormal pH; n = 24), EoE (confirmed with

253 ase was found for patients with severe GERD (esophagitis or Barrett esophagus) after surgery [SIR 6.0

254 nalyses of patients with severe GERD (reflux esophagitis or Barrett esophagus) showed similar results

255 In a prospective study of patients with esophagitis or Barrett's esophagus, we found belt compre

256 zumab did not alter symptoms of eosinophilic esophagitis or eosinophil counts in biopsy samples compa

257 cantly lower in patients with GERD (erosive esophagitis or nonerosive but pH-abnormal GERD) or eosin

258 d biopsy, those with histologic evidence for esophagitis or normal histology findings are at increase

259 and acid-related complications (ie, erosive esophagitis or peptic stricture) should take a PPI for s

260 umab did not reduce symptoms of eosinophilic esophagitis or tissue eosinophil counts compared with pl

261 E at endoscopy (P < 0.001), and histological esophagitis (P = 0.02).

262 interleukin-9 are important in eosinophilic esophagitis pathogenesis.

263 ta production and signaling, to eosinophilic esophagitis pathophysiology.

264 Eosinophilic esophagitis patients were stratified based on the diagno

265 s without GERD or patients with eosinophilic esophagitis; patients with GERD had low MI closer to the

266 acute disorders, such as gastric ulcers and esophagitis, PPIs are now commonly used for prolonged du

267 The prevalence rate of reflux esophagitis (RE) in Asia, including Taiwan, has increase

268 ctic sensitivity to peanut, (2) eosinophilic esophagitis related to cow's milk, and (3) delayed anaph

269 Esophagitis reversal was observed in 92% patients in gro

270 Studies on eosinophilic esophagitis show a relationship to connective tissue dis

271 The patients, stratified by esophagitis status, were randomly assigned (1:1:1:1) to

272 We also discuss eosinophilic esophagitis subtypes, factors associated with disease, a

273 nary study of 12 patients with severe reflux esophagitis successfully treated with PPI therapy, stopp

274 terans Affairs Medical Center who had reflux esophagitis successfully treated with proton pump inhibi

275 s, allergic conjunctivitis, and eosinophilic esophagitis), suggesting both cutaneous and systemic imm

276 The Pediatric Eosinophilic Esophagitis Symptom Score (PEESS v2.0) measures patient-

277 rosive but pH-abnormal GERD) or eosinophilic esophagitis than in patients without GERD or patients wi

278 ized that this platform can be used to model esophagitis to better understand the interactions betwee

279 ality of life (HRQoL) with healing of reflux esophagitis to further derive insights into the underlyi

280 anscriptome overlapped with the eosinophilic esophagitis transcriptome.

281 tome markedly distinct from the eosinophilic esophagitis transcriptome.

282 5 % of the on-demand group developed reflux esophagitis versus none in the continuous group (P < 0.0

283 The long-term prevalence of esophagitis was 28% and BE was 8%.

284 Reflux esophagitis was detected in 24 (45%), 17 (32%), and 10 p

285 Esophagitis was found at endoscopy in 34% and confirmed

286 At long-term follow-up, esophagitis was found in 14 group A (30%) and in 18 grou

287 study was continued, a study of eosinophilic esophagitis was initiated, and new therapeutic trials we

288 oscopic and histological characterization of esophagitis was performed according to the Los Angeles a

289 Reflux esophagitis was seen in 17 cases (32.7%) of SSc and only

290 Rates of grade 2 and 3 acute esophagitis were 18 (28%) and 5 (8%), respectively.

291 626 patients with reflux esophagitis were enrolled into one of two treatment grou

292 h eosinophilic skin diseases or eosinophilic esophagitis were used for in vivo analyses.

293 Esophagitis, whether caused by acid reflux, allergic res

294 corticoid-treated patients with eosinophilic esophagitis who had 2 consecutive endoscopic biopsy spec

295 al tissues from 2 patients with eosinophilic esophagitis who underwent esophagectomy and 47 consecuti

296 rs the role of the allergist in eosinophilic esophagitis with a focus on the literature from the past

297 In this investigation, we asked whether esophagitis with an eosinophilic component is observed i

298 Esophagitis with eosinophilia, inflammation, and fibrosi

299 MI patterns identified patients with esophagitis with higher levels of specificity (95%) and

300 l toxicity was esophagitis (29% grade 3 or 4 esophagitis, with one patient with grade 3 tracheoesopha